Nevo Y, Pestronk A, Kornberg A J, Connolly A M, Yee W C, Iqbal I, Shield L K
Department of Neurology, Barnes Hospital, Washington University School of Medicine, St. Louis, MO, USA.
Neurology. 1996 Jul;47(1):98-102. doi: 10.1212/wnl.47.1.98.
Chronic inflammatory demyelinating neuropathy (CIDP) is a rare disease in childhood. We reviewed the clinical characteristics, response to therapy, and long-term prognosis in 13 children (1.5 to 16 years of age) diagnosed with CIDP at Washington University Medical Center, St. Louis, and the Royal Children's Hospital, Melbourne, Australia, between 1979 and 1994. The most common presenting symptom (in 11/13 [85%]) was lower extremity weakness associated with difficulty in walking. Preceding events within 1 months of onset, mostly intercurrent infections or vaccinations, occurred in seven children (54%). The disease was monophasic in three children (23%). One relapse occurred in four (30%) and multiple relapses in six (46%). All patients had at least short-term response to steroids. Three children (23%) recovered completely during the first year. Ten children (77%) had residual weakness after an average follow-up of 6 years. There seems to be two populations of children with CIDP. One subgroup, with a favorable prognosis, progressed to peak disability over less than 3 months; these children often have a monophasic course with complete resolution of symptoms and signs and withdrawal from all medications by 1 year after onset. A second subgroup progressed for 3 months or longer; these children all required substantial does of prednisone for prolonged periods and had considerable long-term morbidity with persistent weakness.
慢性炎症性脱髓鞘性多发性神经病(CIDP)在儿童中是一种罕见疾病。我们回顾了1979年至1994年间在华盛顿大学医学院(圣路易斯)以及澳大利亚墨尔本皇家儿童医院被诊断为CIDP的13名儿童(年龄在1.5至16岁之间)的临床特征、治疗反应及长期预后情况。最常见的首发症状(11/13 [85%])是下肢无力伴行走困难。7名儿童(54%)在发病1个月内有前驱事件,大多是并发感染或接种疫苗。3名儿童(23%)病情为单相性。4名儿童(30%)复发1次,6名儿童(46%)多次复发。所有患者对类固醇至少有短期反应。3名儿童(23%)在第一年完全康复。平均随访6年后,10名儿童(77%)仍有残留无力症状。似乎有两类CIDP患儿。一个亚组预后良好,在不到3个月的时间里发展至最大残疾程度;这些儿童通常病程为单相性,症状和体征完全消退,发病后1年内停用所有药物。第二个亚组病程持续3个月或更长时间;这些儿童都需要长期大量使用泼尼松,并且长期存在明显的发病率,伴有持续无力症状。